Does the anti-prothrombin antibodies measurement provide additional information in patients with thrombosis?

被引:30
作者
Bardin, Nathalie
Alessi, Marie Christine
Dignat-George, Francoise
Vague, Irene Julian
Sampol, Jose
Harle, Jean Robert
Sanmarco, Marielle
机构
[1] Hop Conception, Federat Autoimmunite Thrombose, Immunol Lab, F-13005 Marseille, France
[2] Univ Aix Marseille 2, INSERM, U608, UFR Pharm, Marseille, France
[3] Hop Enfants La Timone, Hematol Lab, Marseille, France
[4] Hop Conception, Serv Med Interne, Marseille, France
关键词
anti-prothrombin antibodies; thrombosis; antiphospholipid antibodies; IgG-aPS/PT; IgG-aPT; IgG-a beta(2)GPI;
D O I
10.1016/j.imbio.2007.02.001
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The aim of this study is to get new insight into the relevance of IgG anti-prothrombin antibodies in patients with thrombosis and to determine whether human prothrombin alone (aPT) or complexed to phosphatidylserine (aPS/PT) should be preferentially used for measuring these antibodies by enzyme-linked immunosorbent assay (ELISA). To this end, prevalence of anti-prothrombin antibodies, their characteristics in terms of avidity and heterogeneity, and their relationship with anti-beta 2 glycoprotein I antibodies (a beta 2GPI) were studied in 152 patients with thrombosis. Patients were divided into two groups according to the presence or absence of antiphospholipid antibodies (aPL), called aPL+ or aPL-, respectively. In the aPL- group (n = 90), the prevalence of anti-prothrombin antibodies was substantial (10%) but not significantly different from that of control (5%). In the aPL+ group (n = 62), lupus anticoagulant (LA) or anticardiolipin antibodies (aCL) positive, 61% were positive for anti-prothrombin antibodies with no statistical difference between aPT and aPS/PT prevalence (42% vs. 55%, respectively). In the whole thrombotic population, 19% were only aPT and 34% only aPS/PT suggesting the presence of different antibodies. Absorption experiments confirmed the heterogeneity of aPT and aPS/PT. No difference in their avidity was demonstrated. From the aPL+ group, 60 were LA positive. Among them, 18% were negative for a beta 2GPI and anti-prothrombin antibodies showing that the detection of these antibodies could not substitute for LA determination. In conclusion, our data show that the screening of the different anti-prothrombin antibodies is not warranted in the aPL+ group since these antibodies do not provide additional information compared to aCL, LA and/or a beta 2GPI measurement. Nevertheless, the substantial prevalence of anti-prothrombin antibodies in the aPL- group should be further explored in a large prospective study. (c) 2007 Elsevier GmbH. All rights reserved.
引用
收藏
页码:557 / 565
页数:9
相关论文
共 36 条
[1]  
Akimoto T, 1999, J RHEUMATOL, V26, P580
[2]   Antiprothrombin autoantibodies in severe preeclampsia and abortion [J].
Akimoto, T ;
Akama, T ;
Saitoh, M ;
Kono, I ;
Sumida, T .
AMERICAN JOURNAL OF MEDICINE, 2001, 110 (03) :188-191
[3]  
ARVIEUX J, 1995, THROMB HAEMOSTASIS, V74, P1120
[4]  
Atsumi T, 2000, ARTHRITIS RHEUM-US, V43, P1982, DOI 10.1002/1529-0131(200009)43:9<1982::AID-ANR9>3.0.CO
[5]  
2-2
[6]   Antiprothrombin antibodies-are they worth assaying? [J].
Atsumi, T ;
Amengual, O ;
Yasuda, S ;
Koike, T .
THROMBOSIS RESEARCH, 2004, 114 (5-6) :533-538
[7]  
Barcat D, 1999, J RHEUMATOL, V26, P1007
[8]  
Bertolaccini Maria Laura, 2004, Clin Lab, V50, P653
[9]  
Bertolaccini ML, 1998, J RHEUMATOL, V25, P1104
[10]   Antiprothrombin antibodies detected in two different assay systems - Prevalence and clinical significance in systemic lupus erythematosus [J].
Bertolaccini, ML ;
Atsumi, T ;
Koike, T ;
Hughes, GRV ;
Khamashta, MA .
THROMBOSIS AND HAEMOSTASIS, 2005, 93 (02) :289-297